Pfizer Agrees to Settle EpiPen Suit for $345 Million

Pfizer has agreed to a $345 million settlement of a class action antitrust suit over the EpiPen, an epinephrine auto-injector used in the emergency treatment of anaphylaxis.

The proposed settlement filed in the U.S. District Court for the District of Kansas does not end the case against the other defendant, generics giant Mylan, which manufactures the product.

In February, U.S. District Judge Daniel Crabtree certified two classes in the antitrust suit against Pfizer and Mylan over an alleged scheme to raise the price of EpiPen. The judge, who previously dismissed most of the claims against Mylan in June, must sign off on the Pfizer settlement before it can go ahead.